<DOC>
	<DOCNO>NCT02277106</DOCNO>
	<brief_summary>Stage 1 double-blind , proof-of-concept study design evaluate safety , tolerability , PK , efficacy SAGE-547 Injection male female patient essential tremor upper limb . Stage 2 open-label arm design evaluate safety , tolerability , PK , effeciveness SAGE-547 Injection high dose Stage 1 . Subjects complete Stage 1 invited participate Stage 2 .</brief_summary>
	<brief_title>Evaluate SAGE-547 Patients With Essential Tremor</brief_title>
	<detailed_description />
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>Males female , 3575 year old diagnosis essential tremor symptom clearly present least 1 upper limb ; patient tremor present least 2 year prior Screening Off medication , stable dose medication tremor least 28 day prior Screening Recent history active clinically significant manifestation metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , musculoskeletal , dermatological , urogenital , eye , ear , nose , throat , psychiatric , neurological ( essential tremor ) disorder Medical history seizure</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>